Bristol-Myers Squibb Co


Latest Trade






Today's Range




52 Week Range




As of on the New York Stock Exchange ∙ Minimum 15 minute delay


Previous Close
3M AVG Volume
Today's High
Today's Low
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Forward P/E
Dividend (Yield %)

Next Event

Dividend For BMYMP.PK - 0.5000 USD

Latest Developments


Evotec Expands Neuroscience Collaboration With Bristol Myers Squibb

BioAtla Announces Clinical Collaboration With Bristol Myers Squibb To Study Mecbotamab Vedotin (Ba3011) And Ozuriftamab Vedotin (Ba3021) In Combination With Opdivo® (Nivolumab) For Treatment Of

Century Therapeutics, Bristol Myers Enter Collaboration To Develop IPSC-Derived Allogeneic Cell Therapies


About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.


Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14



United States


Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

David V. Elkins

Executive Vice President and Chief Financial Officer Member of the Leadership Team

Ann M. Powell

Chief Human Resource Officer, Senior Vice President Member of the Leadership Team

Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

Christopher S. Boerner

Executive Vice President and Chief Commercial Officer, Member of the Leadership Team

Key Stats

2.13 mean rating - 23 analysts
Revenue (MM, USD)
















Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)

Latest News

Latest News

Bristol Myers sees slight 2022 sales growth due to sharply lower Revlimid sales

Bristol Myers Squibb Co said it expects significantly lower 2022 sales from its top-selling drug Revlimid as patents on the drug begin to expire, limiting total company sales to low-single digit growth for the year.

Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention

Bristol Myers Squibb Co's Orencia on Wednesday became the first drug to win U.S. approval for the prevention of acute Graft versus Host Disease (aGvHD), a potentially fatal complication that could occur after a stem cell transplant.

U.S. FDA approves Bristol Myers' drug to prevent transplant complication

The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Bristol Myers Squibb Co's drug Orencia to prevent acute graft versus host disease.

Bristol Myers enters up to $920 million deal with Immatics for cancer drug

Drugmaker Bristol Myers Squibb has agreed to spend up to $920 million for global exclusive rights to an experimental immunotherapy developed by Immatics NV, the companies said on Tuesday.

Bristol Myers is sued for refusing COVID-19 vaccine religious exemptions

Bristol Myers Squibb Co was sued on Wednesday by four employees who said the drugmaker refused to grant them religious exemptions from its COVID-19 vaccination requirement, and threatened to fire them on Dec. 6 for remaining unvaccinated.

Bristol Myers is sued for refusing COVID-19 vaccine religious exemptions

Bristol Myers Squibb Co was sued on Wednesday by four employees who said the drugmaker has refused their requests for religious exemptions from getting COVID-19 vaccines, and threatened to fire them next Monday if they were not vaccinated.

U.S. FDA extends review of Bristol Myers' heart disease drug

The U.S. health regulator has extended the review of Bristol Myers Squibb's oral heart disease drug candidate mavacamten, which the company acquired in its $13 billion buyout of MyoKardia last year.

J&J sees potential for 14 new multibillion-dollar drugs by 2025

Johnson & Johnson expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company's pharmaceuticals unit on Thursday.

Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound

Bristol Myers Squibb Co on Wednesday said its third-quarter sales rose 10% and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year.

Bristol Myers interested in buying Aurinia Pharma - Bloomberg News

Bristol Myers Squibb Co has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals Inc, Bloomberg News reported on Friday, citing people familiar with the matter.

Bristol-Myers to require U.S., Puerto Rico staff to be vaccinated

Bristol-Myers Squibb Co will require all its employees working in the United States and Puerto Rico to be fully vaccinated against the coronavirus effective Nov. 1, the drugmaker said on Tuesday.

Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers

(Corrects paragraph 1 and 2 to show one patent, not patents)

REFILE-Gilead Sciences wins reversal of $1.2 bln fine against Bristol Myers in patent case

Gilead Sciences Inc escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb patent that Gilead's Yescarta cancer drug allegedly infringed were invalid.

Bristol Myers sees return to growth for Opdivo, tops estimates

Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.

Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate

Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.

Bristol-Myers and Eisai to jointly develop, market cancer drug

Bristol-Myers Squibb Co and Eisai Co on Thursday entered into an agreement to jointly develop and market an experimental cancer drug.

Bristol-Myers is sued for $6.4 billion over delayed cancer drug

Bristol Myers Squibb Co was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.

Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug

A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.

U.S. FDA approves Bristol Myers' bowel disease treatment

Bristol Myers Squibb said on Thursday the U.S. Food and Drug Administration approved its oral drug Zeposia to treat adults with ulcerative colitis, a chronic inflammatory bowel disease.

Roche aims Tecentriq at early lung cancer after data shows benefit

An immunotherapy showed for the first time it can help early-stage lung cancer patients survive longer without their disease returning, according to data on Wednesday, a potential turning point for such drugs to be used before tumours spread.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.